Replies to post #30058 on Marker Therapeutics Inc (MRKR)

[MDtoB22]

Exactly. In my opinion, MRKR’s lymphoma study should be #2 behind AML. The data are mature and demonstrate durable responses in both adjuvant and active disease. The patients treated were also highly refractory. The pancreatic cancer trial is more experimental than anything else at this point in time.